Total Payments
$4,288
2024 Payments
$27.16
Companies
37
Transactions
273
Medicare Patients
1,844
Medicare Billing
$249,887
Payment Breakdown by Category
Food & Beverage$4,288 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,288 | 273 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $850.97 | 61 | $0 (2023) |
| Novo Nordisk Inc | $401.95 | 30 | $0 (2023) |
| PFIZER INC. | $371.93 | 24 | $0 (2022) |
| Merck Sharp & Dohme LLC | $344.53 | 23 | $0 (2024) |
| Biohaven Pharmaceuticals, Inc. | $246.41 | 11 | $0 (2021) |
| Eisai Inc. | $155.97 | 8 | $0 (2021) |
| GlaxoSmithKline, LLC. | $148.28 | 11 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $147.63 | 10 | $0 (2019) |
| Allergan, Inc. | $141.15 | 9 | $0 (2020) |
| Clarus Therapeutics Inc. | $134.62 | 8 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $27.16 | 1 | Merck Sharp & Dohme LLC ($27.16) |
| 2023 | $471.34 | 26 | ABBVIE INC. ($155.28) |
| 2022 | $1,224 | 75 | ABBVIE INC. ($326.37) |
| 2021 | $1,662 | 113 | AbbVie Inc. ($323.97) |
| 2020 | $549.56 | 38 | PFIZER INC. ($98.11) |
| 2019 | $222.08 | 11 | Allergan Inc. ($91.08) |
| 2018 | $115.61 | 8 | Janssen Pharmaceuticals, Inc ($88.69) |
| 2017 | $16.89 | 1 | Relypsa, Inc. ($16.89) |
All Payment Transactions
273 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/08/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), CAPVAXIVE, GARDASIL 9 | Food and Beverage | In-kind items and services | $27.16 | General |
| Category: VACCINE | ||||||
| 05/31/2023 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.62 | General |
| Category: Diabetes | ||||||
| 05/26/2023 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/25/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $28.21 | General |
| Category: NEUROSCIENCE | ||||||
| 05/24/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $13.10 | General |
| Category: NEUROSCIENCE | ||||||
| 05/23/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug), SHINGRIX | Food and Beverage | In-kind items and services | $13.39 | General |
| Category: RESPIRATORY | ||||||
| 05/22/2023 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: Bone Health | ||||||
| 05/17/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: NEUROSCIENCE | ||||||
| 05/13/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $27.46 | General |
| Category: NEUROSCIENCE | ||||||
| 05/10/2023 | Nevro Corp. | Senza (Device) | Food and Beverage | In-kind items and services | $14.76 | General |
| Category: Spinal Cord Stimulator | ||||||
| 05/04/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.23 | General |
| Category: NEUROSCIENCE | ||||||
| 05/03/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: Gastroenterology | ||||||
| 04/12/2023 | GlaxoSmithKline, LLC. | BEXSERO (Biological), SHINGRIX | Food and Beverage | In-kind items and services | $15.71 | General |
| Category: VACCINES | ||||||
| 04/11/2023 | Merck Sharp & Dohme LLC | STEGLATRO (Drug), BELSOMRA | Food and Beverage | In-kind items and services | $17.02 | General |
| Category: ENDOCRINOLOGY | ||||||
| 04/06/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.16 | General |
| Category: NEUROSCIENCE | ||||||
| 03/25/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: PSYCHIATRY | ||||||
| 03/17/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.30 | General |
| Category: NEUROSCIENCE | ||||||
| 03/14/2023 | Merck Sharp & Dohme LLC | STEGLATRO (Drug), BELSOMRA | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: ENDOCRINOLOGY | ||||||
| 02/27/2023 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $17.99 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/24/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $28.94 | General |
| Category: PSYCHIATRY | ||||||
| 02/23/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: Diabetes | ||||||
| 02/14/2023 | Merck Sharp & Dohme LLC | STEGLATRO (Drug), BELSOMRA | Food and Beverage | In-kind items and services | $14.98 | General |
| Category: ENDOCRINOLOGY | ||||||
| 02/08/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), BEXSERO | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: VACCINES | ||||||
| 02/07/2023 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $23.95 | General |
| Category: Infectious Diseases | ||||||
| 01/26/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.09 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 423 | 1,054 | $366,049 | $78,215 |
| 2022 | 25 | 611 | 1,251 | $280,707 | $79,837 |
| 2021 | 19 | 529 | 875 | $209,375 | $60,504 |
| 2020 | 9 | 281 | 560 | $118,290 | $31,331 |
Total Patients
1,844
Total Services
3,740
Medicare Billing
$249,887
Procedure Codes
67
All Medicare Procedures & Services
67 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 121 | 462 | $198,633 | $37,976 | 19.1% |
| 99487 | Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 36 | 168 | $53,820 | $15,888 | 29.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 22 | 90 | $21,690 | $5,450 | 25.1% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 17 | 17 | $17,605 | $4,775 | 27.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 37 | 37 | $17,695 | $4,572 | 25.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 30 | 30 | $19,837 | $2,388 | 12.0% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 13 | 58 | $10,708 | $2,126 | 19.9% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 12 | 54 | $7,840 | $1,938 | 24.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 18 | $5,058 | $927.06 | 18.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 61 | 61 | $5,252 | $572.42 | 10.9% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2023 | 11 | 11 | $4,211 | $565.74 | 13.4% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 16 | 16 | $1,248 | $472.16 | 37.8% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 17 | 17 | $1,279 | $299.03 | 23.4% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 15 | 15 | $1,173 | $263.85 | 22.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 105 | 406 | $127,890 | $33,348 | 26.1% |
| 99487 | Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 42 | 181 | $47,965 | $17,604 | 36.7% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2022 | 23 | 106 | $13,780 | $4,363 | 31.7% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2022 | 22 | 102 | $10,710 | $3,896 | 36.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 29 | 29 | $9,570 | $3,659 | 38.2% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2022 | 11 | 11 | $7,810 | $2,781 | 35.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 13 | 13 | $8,399 | $1,844 | 22.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 21 | 21 | $10,305 | $1,748 | 17.0% |
| 96130 | Evaluation of psychological test, first hour | Office | 2022 | 17 | 17 | $6,290 | $1,598 | 25.4% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2022 | 26 | 26 | $10,400 | $1,589 | 15.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 23 | $4,883 | $1,211 | 24.8% |
About Dr. Ali Khan, MD
Dr. Ali Khan, MD is a Family Medicine healthcare provider based in Marana, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/06/2010. The National Provider Identifier (NPI) number assigned to this provider is 1760714380.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ali Khan, MD has received a total of $4,288 in payments from pharmaceutical and medical device companies, with $27.16 received in 2024. These payments were reported across 273 transactions from 37 companies. The most common payment nature is "Food and Beverage" ($4,288).
As a Medicare-enrolled provider, Khan has provided services to 1,844 Medicare beneficiaries, totaling 3,740 services with total Medicare billing of $249,887. Data is available for 4 years (2020–2023), covering 67 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Other Specialties Family Medicine
- Location Marana, AZ
- Active Since 02/06/2010
- Last Updated 07/20/2015
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1760714380
Products in Payments
- VRAYLAR (Drug) $402.60
- NURTEC ODT (Drug) $367.20
- UBRELVY (Drug) $268.23
- Ozempic (Drug) $177.09
- Dayvigo (Drug) $155.97
- BELSOMRA (Drug) $149.96
- XARELTO (Drug) $147.63
- QULIPTA (Drug) $141.16
- JATENZO (Drug) $134.62
- Vascepa (Drug) $117.69
- PREMARIN (Drug) $117.25
- XIFAXAN (Drug) $116.50
- JARDIANCE (Drug) $112.82
- SHINGRIX (Biological) $104.77
- Saxenda (Drug) $104.31
- XIENCE SIERRA (Device) $93.93
- AVYCAZ (Drug) $91.08
- EVENITY (Biological) $84.65
- NEXLETOL (Drug) $83.72
- JANUVIA (Drug) $80.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.